India, as a major player in the global pharmaceutical industry, holds a significant position in the international market with its high-quality medicines and cost-effectiveness. The country supplies over 50% of the world’s vaccines, 40% of generics used in the United States, and 25% of generics used in the UK. The domestic industry is vast, with around 3,000 pharmaceutical companies and approximately 10,500 production units. The pharmaceutical industry contributes significantly to the country's economy, accounting for about 1.72% of the GDP. Globally, India ranks third in terms of output and fourteenth in terms of value.

With continuous advancements in innovative drug research and the growing global health demands, Indian pharmaceutical companies are experiencing unprecedented growth opportunities. Recently, Forbes India published an article titled "Top 10 Pharmaceutical Companies by Market Value in India", which is summarized in the following table (Lakh Crore equals one trillion):

Guideview has compiled the total revenue for 2024 based on the financial reports of each company (all figures are converted to natural year revenue, calculated from Q4FY2024 to Q3FY2025 in the Indian fiscal year), as shown in the table below for reference.

Sun Pharma

Sun Pharma ranks first among the top ten pharmaceutical companies in India. As one of the leading companies in the Indian pharmaceutical industry, Sun Pharma has a strong position in the global market due to its powerful R&D capabilities, diverse product portfolio, and extensive market reach. In 2024, Sun Pharma’s total sales were ?510.39 billion (approximately $5.869 billion), a 9.36% year-over-year increase.

In terms of formulations, the total sales amounted to ?488.445 billion ($5.617 billion). Regionally, the Indian formulations sales were ?164.179 billion ($1.888 billion), a 12% increase; US formulations sales were ?161.743 billion ($1.86 billion), up by 8%; emerging markets sales were ?91.946 billion ($1.057 billion), growing by 9%; and other regions had sales of ?70.577 billion ($812 million), rising by 6%.

The company’s product range includes treatments for psychiatric, neurological, kidney, gastrointestinal, orthopedic, ophthalmic diseases, and disorders, as well as cardiovascular products. Sun Pharma’s R&D pipeline includes seven molecules undergoing clinical trials. The company has a comprehensive product portfolio in the US market, with 541 approved ANDAs, and 109 ANDAs awaiting FDA approval. Additionally, the product portfolio includes 51 approved NDAs, with 13 NDAs still awaiting FDA approval.

Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories, a public pharmaceutical company (stock code: RDY), was founded in 1984 and is headquartered in Hyderabad, India. It was listed on the New York Stock Exchange in 2001 (current market capitalization is $11.79 billion). DRL operates globally with key markets including the United States, India, Russia, CIS countries, and Europe.

In 2024, DRL's total revenue was ?311.305 billion (approximately $3.58 billion), a 14.74% year-over-year growth, driven by the revenue from its recently acquired nicotine replacement therapy (NRT) portfolio, and increased income from India and emerging markets. R&D expenditure was ?27 billion ($310 million), a 26% year-over-year increase. Global generic drug revenue was ?278.378 billion ($3.201 billion), growing by 16.7%, primarily driven by the NRT portfolio's revenue, higher sales, and the launch of new products.

The company signed a voluntary licensing agreement with Gilead to produce and commercialize the HIV treatment drug Lenacapavir in over 120 countries. Its subsidiary, Aurigene Oncology Limited, announced promising results for the first-phase study of a novel autologous CAR-T cell therapy for multiple myeloma in India. The partnership with Alvotech completed the filing of a Denosumab biosimilar in the US and Europe, and the launch of Toripalimab in India, an immuno-oncology drug for the treatment of nasopharyngeal cancer. The company also launched Elobixibat in India, a first-in-class drug for the treatment of chronic constipation, marketed as BixiBat?.

As of December 31, 2024, the company held ?13.032 billion ($150 million) in cash and cash equivalents.

Aurobindo Pharma

Aurobindo Pharma is a global pharmaceutical company headquartered in Hyderabad, India. The company primarily manufactures generic drugs and active pharmaceutical ingredients (APIs), with over 500 billion dosage units and 19,000 metric tons of API production capacity across 29 manufacturing plants globally.

The company operates in six major therapeutic areas: antibiotics, antiretrovirals (primarily for treating AIDS), cardiovascular products, central nervous system drugs, gastrointestinal medications, and antihistamines. In addition, it produces dietary supplements, OTC health management drugs, and APIs such as peptides. Aurobindo sells products in over 150 countries, with more than 90% of its revenue coming from international operations, and key marketing partners include AstraZeneca and Pfizer.

In 2024, Aurobindo's total revenue was ?309.22 billion ($3.556 billion), a 10.85% year-over-year increase. Formulations revenue was ?265.98 billion ($3.059 billion), up 14% from the previous year. The US formulation market generated ?143.44 billion ($1.65 billion), an 8% increase, while the European formulation market generated ?80.4 billion ($925 million), a 15% increase. API business revenue remained relatively stable at ?42.73 billion ($491 million).

As of December 31, 2024, the company had submitted 853 ANDAs to the US FDA, with 678 final approvals and 26 tentative approvals. In Q3FY2025, four new ANDAs were submitted, and eight ANDAs received final approval.

Cipla

Cipla, founded by Dr. K. A. Hamied in 1935, is the third-largest pharmaceutical company in India. The company is a global player, specializing in complex generics, and is a leader in respiratory disease treatments in the Indian market. Cipla has a strong presence in respiratory, urology, cardiology, anti-infective, and central nervous system treatments. It currently operates in 46 manufacturing facilities worldwide, producing over 50 dosage forms and 1,500 products.

In 2024, Cipla’s revenue was ?269.81 billion ($3.103 billion), a 6% increase from the previous year. The company divides its operations into six business segments. The Indian domestic market accounts for 55% of Cipla's revenue, North America is the second-largest market at 38%, and Sub-Saharan Africa contributes 17%. International markets (including Europe and emerging markets) account for 16%, while API business revenue contributes 3% and other businesses 1%.

Cipla currently holds seven active approvals. Its Esomeprazole Magnesium delayed-release oral suspension is part of the ninth batch of centralized procurement, and its Dapagliflozin tablets were approved for import in June 2024, effectively bypassing AstraZeneca's patent restrictions, posing a threat to domestic competitors.

Lupin

Lupin is an innovation-driven multinational pharmaceutical company headquartered in Mumbai, India. The company has developed and commercialized various branded and generic formulations, biotechnology products, and APIs across more than 100 markets, including the US, India, South Africa, APAC, LATAM, Europe, the Middle East, and more. Lupin focuses on pediatric, cardiovascular, anti-infective, diabetes, asthma, and anti-tuberculosis drugs. The company actively pursues global expansion through strategic acquisitions and entry into new markets.

Lupin's total revenue was ?199.62 billion ($2.296 billion), a 14.03% increase compared to the previous year. North America contributed ?89.1 billion ($891 million), a 14.1% growth, and the Indian domestic market contributed ?86 billion ($860 million), up by 14.3%. The company invested ?16.58 billion ($190 million) in R&D in 2024.

In Q3FY2025 (October 1–December 31, 2024), Lupin received US FDA approval for six ANDAs. As of December 31, 2024, the company had submitted a total of 430 ANDAs to the US FDA, with 334 approvals to date. It currently holds 49 first-time filings (FTF), including 17 exclusive FTF opportunities. As of December 31, 2024, Lupin had submitted 156 DMF filings in the US.

Summary

The Indian pharmaceutical industry is primarily driven by generics, with 90% of companies focusing on generic drug production. Additionally, India has a strong presence in the API sector and is the second-largest exporter of APIs globally. In terms of formulations and biologics, India accounts for 73.31% of total exports. The top five export markets for Indian pharmaceuticals are the United States, the United Kingdom, South Africa, Russia, and Nigeria. Over the next decade, Indian pharmaceutical companies will aggressively venture into innovative drugs and complex generics, focusing on developing platforms for mRNA, cell, and gene therapies. The Indian biotech market is expected to grow at a compound annual growth rate (CAGR) of 22% in the coming years.

The Indian pharmaceutical industry is expected to experience significant growth between 2023 and 2032, driven by government support policies such as the Production-Linked Incentive (PLI) scheme, aimed at boosting domestic production of key starting materials (KSMs), pharmaceutical intermediates (DIs), and APIs. On August 17, 2023, the Indian Pharmaceutical Regulatory Authority (DOP) proposed the PRIP scheme to encourage the development of orphan drugs and new drug-device combinations, complementing the PLI scheme. The PRIP scheme has a funding budget of ?50 billion (approximately $4.3 billion). Other factors such as healthcare industry growth, increasing lifestyle diseases, demand for affordable healthcare systems, technological advancements, the emergence of telemedicine, and the spread of healthcare insurance will also drive the pharmaceutical industry’s growth.

Challenges facing the industry include the high dependence on imports for active pharmaceutical ingredients (APIs) and key starting materials (KSMs), stringent government regulations, lack of awareness about pharmaceuticals and healthcare in rural areas, raw material price fluctuations, and high transportation and logistics costs. However, technological advances and innovations in the healthcare and pharmaceutical sectors are expected to create favorable opportunities in the market.

Top 5 Indian Pharmaceutical Companies 2025